Ideaya rises as it starts early-stage trial of combination of cancer drugs

IDEAYA Biosciences

30/03/2026 11:45

** Shares of drugmaker Ideaya Biosciences IDYA.O rise 2% to $30.80 premarket

** Co says it began treating patients in an early-stage trial of a combination of two experimental cancer drugs

** The study tests IDE849, which targets DLL3, a protein found on some cancer cells, with IDE161, which blocks a DNA repair process tumors use to survive

** Co says the combo aims to cause more DNA damage in cancer cells, making tumors harder to grow back

** Trial includes patients with solid tumors such as small cell lung cancer and melanoma, across North America, Europe, Australia, South America and Asia

** In an ongoing study of IDE849 alone, co says 3 of 4 previously treated small cell lung cancer patients showed partial tumor shrinkage

** Co says more data on the combo and IDE849 alone are expected in the second half of 2026

** Shares up ~35% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))